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Achieving efficient cardiac gene transfer in a large ani-
mal model has proven to be technically challenging. Pre-
vious strategies have used cardiopulmonary bypass or 
dual catheterization with the aid of vasodilators to deliver 
 vectors, such as adenovirus, adeno-associated virus (AAV), 
or plasmid DNA. Although single-stranded AAV (ssAAV) 
vectors have shown the greatest  promise, they suffer from 
delayed expression, which might be circumvented using 
self-complementary vectors. We sought to optimize car-
diac gene transfer using a percutaneous transendocar-
dial injection catheter to deliver adeno- associated viral 
vectors to the canine myocardium. Four vectors were 
evaluated—ssAAV9, self- complementary AAV9 (scAAV9), 
scAAV8, scAAV6—so that comparison could be made 
between single-stranded and  self-complementary vec-
tors as well as among serotypes 9, 8, and 6. We dem-
onstrate that scAAV is superior to ssAAV and that AAV 6 
is superior to the other serotypes evaluated. Biodistribu-
tion studies revealed that vector genome copies were 
15–4,000 times more abundant in the heart than in any 
other organ for scAAV6. Percutaneous transendocardial 
injection of scAAV6 is a safe, effective method to achieve 
efficient cardiac gene transfer.
Received 24 March 2008; accepted 27 August 2008; published online  
23 September 2008. doi:10.1038/mt.2008.202
IntroductIon
Gene therapy has great therapeutic potential. Adeno-associated 
virus (AAV)-mediated gene therapy has been described exten-
sively in the literature resulting in efficient cardiac gene transfer in 
small animal models, including mice,1–8 rats,9 and hamsters,10 and 
from these reports it appears that serotype 9 (AAV9) is superior 
to other serotypes in the heart.3,4,7,8 In addition to being efficient, 
AAV-mediated transgene expression is also stable, an advantage 
over other commonly used vectors such as adenovirus or plas-
mid DNA.6 However, AAV vectors have the significant disadvan-
tage of delayed expression, taking nearly 1 month to reach full 
expression,11 which would limit their usefulness in a rapidly pro-
gressing  cardiomyopathy. This limitation might be overcome by 
using the recently developed self-complementary AAV (scAAV) 
vectors, which package a double-stranded genome and thus bypass 
the need for complementary strand synthesis. This offers the advan-
tage of faster onset of expression that may also be more efficient 
than traditional single-stranded AAV (ssAAV) vectors, albeit at the 
cost of halving the possible size of the expression cassette.12–16
Although cardiac gene transfer has been extremely successful 
in small animal models, delivery to the heart in large animal mod-
els and humans has proven to be technically challenging. Several 
delivery methods have been investigated with varying degrees 
of success using AAV, adenovirus, or plasmid DNA as vectors. 
Pericardial instillation of vector results in gene transfer that is 
restricted to the epicardium.17,18 Direct, transepicardial injection 
of vector after left thoracotomy allows delivery throughout the left 
ventricular free wall (LVFW); however, this is highly invasive and 
cannot target the interventricular septum (IVS).19–23 Infusion of 
vector into the coronary arteries can lead to efficient gene transfer, 
but optimal transfer often requires highly invasive cardiopulmo-
nary bypass24–28 or dual catheterization of a coronary artery and 
vein29–33 using potentially dangerous pharmacological vasodilators. 
Promising preclinical and phase I/II results have been obtained 
using NOGA left ventricular electromechanical mapping to guide 
transendocardial injections of either plasmid DNA or adenovirus 
via a percutaneously inserted injection catheter.34–37 Although this 
method is relatively noninvasive, it requires creation of a 3D map 
of the heart using very specific and expensive equipment before 
injection. In addition, the gene transfer vectors used in these stud-
ies have been associated with inflammation and unstable expres-
sion in the case of adenovirus, and low efficiency and unstable 
expression in the case of plasmid DNA.38
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Global Gene Transfer to Canine Heart via scAAV6
Our goal in this study was to optimize cardiac gene delivery 
in a large animal model. We focused on AAV vectors because we 
believe that their low immunogenicity and stable, efficient expres-
sion makes them the ideal gene therapy vector for myocardial dis-
eases. We hypothesized that we could achieve safe, efficient, global 
cardiac gene transfer in the canine model with a novel injection 
catheter to deliver scAAV vectors under fluoroscopic guidance. 
We report (i) that percutaneous transendocardial delivery of 
scAAV6 can be used to achieve highly efficient, global gene trans-
fer to the canine heart with rapid onset of expression and (ii) that 
AAV6 is superior to other serotypes tested.
results
study design
In this canine study, we compared the cardiac transduction effi-
ciency of four different AAV vectors 7–10 days after endomyo-
cardial injection via a percutaneously inserted, steerable injection 
catheter. Forty injections were performed to distribute the vector 
globally throughout the LVFW and IVS. Each AAV vector was 
designed to express the enhanced green fluorescent protein (EGFP) 
reporter gene under control of the chicken β-actin promoter with 
cytomegalovirus enhancer (AAV-CB-EGFP). The  vectors evalu-
ated were ssAAV9, scAAV9, scAAV8, and scAAV6 (n = 4 dogs per 
group, 16 total dogs). An additional dog received saline-only injec-
tion to serve as a negative control, and three dogs were injected with 
AAV6 empty capsid for long-term (6 months) safety evaluation. 
By analyzing these vectors, we were able to compare ssAAV with 
scAAV (both AAV9) as well as serotypes 9, 8, and 6 (all scAAV). 
A subset of canines (n = 8), all of which received parvovirus vac-
cine, was screened for the presence of pre-existing antibodies for 
AAV9, 8, and 6. Antibody titer was undetectable for serotypes 8 
and 9, and either undetectable (n = 2) or borderline detectable [1:20 
serum dilution (n = 4) or 1:40 serum dilution (n = 2)] for AAV6.
scAAV9 versus ssAAV9 in the canine myocardium
Based on the reports that AAV9 is the most efficient AAV sero-
type for cardiac gene transfer in mice,3,4,7,8 we first chose to 
assess the efficiency of AAV9-mediated cardiac gene transfer 
in the canine model. In addition, because the newly developed 
scAAV vectors have been used to achieve expression levels 1–2 
logs greater than traditional ssAAV vectors,12–15 we compared the 
gene transfer efficiency of ssAAV9 with scAAV9. A lower dose of 
scAAV9 was used [5 × 1011 genome copies (gc/kg)] compared with 
ssAAV9 (2 × 1013 gc/kg) because we believed that the potentially 
higher efficiency of this scAAV vector would allow us to achieve 
significant gene transfer while minimizing viral load in the subject. 
scAAV9 mediated 50-fold greater cardiac gene transfer expression 
than ssAAV9 at a 40-fold lower dose (P = 0.001), suggesting an 
efficiency advantage of ~3 logs (Figure 1a–d). However, only ~7% 
of the myocardium was transduced in the scAAV9 group (positive 
for GFP expression) (Figure 1e).
scAAV6 versus scAAV8 versus scAAV9  
in the canine myocardium
A vector capable of gene transfer to only 7% of the myocardium 
would have low therapeutic potential. Therefore, we next  evaluated 
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Figure 1 delivery of single-stranded adeno-associated virus 9 (ssAAV9) and self-complementary AAV9 (scAAV9) to the canine heart via 
needle-tip injection catheter. (a) For analysis, the heart was divided into four equal sections through the short axis from base to apex. Green fluo-
rescent protein (GFP) expression in representative cryosections of the heart 7–10 days after injection of either (b) 2 × 1013 genome copies (gc)/kg of 
ssAAV9-CB-EGFP or (c) 5 × 1011 gc/kg of scAAV9-CB-EGFP. Endo, endocardium; Epi, epicardium; IVS, interventricular septum; LVFW, left ventricular 
free wall. Bar = 200 μm. Quantitative analysis of GFP expression reported as either (d) total area positive for GFP or (e) percent cardiomyocyte area 
positive for GFP. Note that scAAV9 is superior to ssAAV9 even at a 40-fold lower dose (*P = 0.001). Error bars represent mean ± SD.
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the cardiac gene transfer efficiency of two additional serotypes, 8 
and 6. Serotype 8 was chosen because it has relatively high car-
diac tropism in the mouse3–5,8 and rat,9 and serotype 6 was chosen 
because it has a relatively high cardiac tropism in the pig when 
compared to serotypes 2 and 5.32,33 We continued the study with 
the superior scAAV vector designed to express CB-EGFP at a dose 
of 5 × 1011 gc/kg. Although the cardiac gene transfer efficiency of 
scAAV8 was similar to that of scAAV9, scAAV6 was significantly 
more efficient than the other vectors evaluated in this study (P = 
0.0001) (Figure 2a–d). With scAAV6, high-level expression of GFP 
was evident throughout the LVFW and IVS in ~60% of the cardio-
myocyte area (Figure 2b and d). Representative 4′-6-diamidino-
2-phenylindole-counterstained sections for each vector and saline 
control can be found in Supplementary Figure S1.
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Figure 2 delivery of self-complementary adeno-associated virus 8 (scAAV8) and scAAV6 to the canine heart via needle-tip injection cath-
eter. Green fluorescent protein (GFP) expression in representative cryosections of the heart 7–10 days following injection of either 5 × 1011 gc/kg 
of (a) scAAV8-CB-EGFP or (b) scAAV6-CB-EGFP. Endo, endocardium; Epi, epicardium; IVS, interventricular septum; LVFW, left ventricular free wall. 
Bar = 200 μm. Quantitative analysis of GFP expression reported as either (c) total area positive for GFP or (d) percent cardiomyocyte area positive for 
GFP. Note that scAAV6 is superior to the other serotypes examined (*P = 0.0001). Error bars represent mean ± SD.
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Figure 3 Biodistribution of adeno-associated virus (AAV) vectors 7–10 days after delivery to the canine heart via needle-tip injection 
catheter. (a) Biodistribution in several organs examined. Go, gonad; He, heart; Ki, kidney; Li, liver; Lu, lung; SM, skeletal muscle; Sp, spleen; 
St, stomach. (b) Tissue tropism of vectors evaluated reported as ratio of vector detected in heart to vector detected in organ of choice. Note 
that self- complementary AAV6 (scAAV6) is highly tropic for cardiac tissue when compared with the other vectors. (c) GFP expression in cryosec-
tions of the liver 7–10 days after treatment. Bar = 40 μm. (d) Quantitative analysis of GFP expression in liver. Note that there are significantly 
fewer positive cells in the scAAV6 group compared with other scAAV serotypes (*P = 0.002). HPF (high power field) (×40). Error bars represent 
mean ± SD.
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Biodistribution of AAV vectors after  
transendocardial injection
AAV vector genomes were detected in all tissues examined 
(Figure 3a); however, the ratio of genomes detected in the heart to 
genomes detected in other tissues varied significantly from vector 
to vector (Figure 3b). Of the four vectors examined, scAAV6 had 
the highest cardiac specificity with heart-to-tissue ratios ranging 
from 15 in the liver to ~100 in the spleen and up to 4,000 in other 
tissues. In contrast, the heart-to-organ ratios for the other vectors 
evaluated were ~2 or less for the liver and 10 or less in the spleen 
(Figure 3b). GFP fluorescence was also minimal in liver sections 
from animals treated with scAAV6 compared to other sc vectors 
(P = 0.002) (Figure 3c and d).
safety of percutaneous transendocardial delivery  
of AAV vectors
There was no mortality associated with our protocol. However, 
ventricular ectopy with secondary hypotension was noted in 14 
of 16 dogs at the time of AAV injection. The dog treated with 
saline only also experienced ventricular ectopy. These arrhyth-
mias were amenable to lidocaine infusion in all 14, and lidocaine 
was discontinued uneventfully once the injections were com-
pleted. Ventricular arrhythmias had resolved in all dogs by the 
time they had recovered from anesthesia. Color flow Doppler 
of the aortic valve, which was performed in a subset of animals 
(n = 6 dogs) before and after procedure, revealed no change in 
valve leakage secondary to transaortic catheterization in all dogs 
examined. Histological analysis of hematoxylin and eosin- and 
trichrome-stained cardiac sections revealed minimal amounts of 
fibrosis and mononuclear cell infiltration at the sites of injection 
(Supplementary Figure S2).
dIscussIon
Cardiac gene therapy has great therapeutic potential, but its appli-
cation has been hindered due to the lack of a safe and effective 
delivery method in a large animal model. We report here a sim-
ple, relatively noninvasive protocol in the canine which results in 
highly efficient, global cardiac gene transfer mediated by scAAV6 
after delivery via a percutaneous injection catheter. This procedure 
is superior to previously reported large animal cardiac gene trans-
fer techniques because it combines the advantages of direct injec-
tion with those of a noninvasive percutaneous delivery system.17–38 
Because it results in high-level transgene expression throughout 
the LVFW and IVS, this technique could be useful to treat dis-
eases which affect the heart globally, such as cardiomyopathy. 
Furthermore, localized delivery is also possible, and importantly 
can be achieved in poorly perfused areas. This offers a tremendous 
advantage over vascular approaches in treating regional ischemia, 
which is important considering that ischemic cardiomyopathy 
accounts for ~40% of all heart failure cases.39
Under fluoroscopic guidance, the catheter is steerable and 
needle-tip length is adjustable so that multiple injections can be 
targeted throughout the left ventricle from base to apex and from 
endocardium to epicardium. Fluoroscopy images recorded during 
the procedure demonstrate how the catheter tip can be deformed 
to target a specific region of the heart and how contrast media is 
used to track injections (Supplementary Figure S3). Therefore, 
the technique lends itself to global gene delivery or targeted gene 
delivery for addressing a regional defect.
Moreover, our delivery method is simple, safe, and relatively 
noninvasive, suggesting it would be better tolerated in patients 
with significant heart disease than procedures requiring thora-
cotomy, cardiopulmonary bypass, or electromechanical map-
ping before injection. The catheter has been safely employed to 
deliver skeletal myoblasts to large animals and humans,40–43 but to 
our knowledge this is the first report of its use for gene delivery. 
The only adverse event associated with the injection procedure 
was ventricular ectopy that was amenable to lidocaine infusion. 
Because ectopy was noted in the saline-injected animal as well, it 
is likely a result of the intramyocardial injections themselves and 
not the AAV vector. Pathology at 7–10 days revealed only small 
fields of fibrosis at the injection sites with minimal mononuclear 
infiltration, which is similar to what was observed following direct 
myocardial injection in a porcine model at 2 weeks.23 Finally, our 
technology does not require the use of expensive and sometimes 
dangerous vasodilators, such as vascular endothelial growth  factor, 
for effective delivery.
Furthermore, we have identified an ideal gene transfer vec-
tor in a large animal model. While many investigators have relied 
on unstable vectors such as adenovirus and plasmid DNA in 
their large animal cardiac models, we have focused on the stable 
scAAV vector with the goal of achieving long-term expression 
with rapid onset. The scAAV vectors contain a mutation in one 
of the  replication termination sequences that allows synthesis 
and packaging of a dimeric inverted repeat.15 As a result, these 
vectors bypass the rate-limiting requirement for second strand 
synthesis and have been reported to be more efficient than the 
traditional ssAAV vectors in several species and tissues.13–15 Our 
findings confirm these previous reports for the first time in the 
canine heart. We demonstrate that scAAV is several logs more 
potent than ssAAV in the canine heart, at least within the short 
time frame of these experiments (7–10 days). It may be that the 
ssAAV expression would approach that of the scAAV over weeks 
to months;44 however, this would still limit its possible therapeutic 
applications as compared with scAAV vectors because many myo-
cardial diseases, such as ischemia/infarction would demand rapid 
onset of expression for ideal therapeutic efficacy. Although we 
did not look for expression earlier than 1 week, small animal data 
suggest that transgene expression mediated by AAV can initiate 
as early as 1–4 days.44,45 Further studies are needed in this canine 
model to determine a time course of expression.
We also observed that AAV6 is ~1 log more potent than AAV8 
and AAV9 in the canine heart. This result was unanticipated based 
on a review of the literature. Although data from porcine hearts 
suggest that AAV6 is superior to 2 and 5,32,33 a study in rats that 
excluded serotype 9 demonstrated the superiority of AAV8 over 
serotypes 1–7 in the heart,9 and three reports in mice demon-
strated that AAV9 is superior to 1 and 8 in the heart.3,4,7 This led 
us to hypothesize that serotype 9 would be superior to 8, which 
would be superior to 6. However, the small animal data did not 
accurately predict the large animal outcome because we observed 
quite the opposite result. Based on our data, scAAV6 is ~1 log 
more potent than the other scAAV vectors evaluated in this study 
(Figure 2d). We screened a subset of our dogs for the presence of 
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pre-existing neutralizing antibodies against AAV9, 8, and 6 and 
detected extremely low-titer antibodies (<1:20 to 1:40 serum dilu-
tion) only for AAV6. Because we observed that AAV6 was the most 
efficient cardiac gene transfer vector, it is unlikely that differential 
titers of pre-existing neutralizing antibodies were responsible for 
the differential cardiac transduction reported in this study.
A recent study examined the mechanism of high-efficiency 
cardiac gene transfer by AAV6 and found that serotype 6 displays 
both enhanced cellular internalization and nuclear uncoating in 
cardiomyocytes compared with serotype 2.16 Perhaps, the canine 
heart contains a higher density of the AAV6 receptor compared 
with other species, and this fact, combined with its high efficiency 
of nuclear uncoating and self-complementary DNA structure, 
may explain the superior performance of scAAV6 in this study. 
Further investigation is needed to confirm this hypothesis. It will 
also be important to conduct future studies to determine the time 
course of expression because this may vary depending on the 
serotype used.
In addition to being highly efficient, scAAV6 is also relatively 
cardiac specific compared with the other serotypes evaluated, 
which further increases its utility as a cardiac gene therapy vec-
tor. In terms of vector biodistribution, the heart-to-liver ratio was 
15 for scAAV6 compared with 2 or less for the other serotypes. 
The heart-to-organ ratio of scAAV6 was also very favorable in 
other organs and ranged from 100 in the spleen up to 4,000 for the 
gonads. This preferential cardiac transduction of AAV6 has also 
been reported in the mouse8 and pig.32 Although the transduced 
cell types in the spleen and other organs were not investigated, 
another report has identified the ability of AAV to transduce 
monocytes in the spleens of nonhuman primates.46
It should be noted, however, that although our canine data 
suggest that AAV6 may be the vector of choice for clinical trials of 
cardiac gene transfer, the human heart may display a different tro-
pism for AAV serotypes. Indeed, a study in nonhuman primates 
showed that AAV9 was able to provide fourfold greater expres-
sion than AAV1 in the heart.4 Although AAV1 and AAV6 share 
>95% sequence homology in their capsids,11 a recent report noted 
that the relative tissue tropisms of AAV1 and 6 were substan-
tially different in several organs examined, including an almost 
2 log advantage for AAV6 in the heart.8 Therefore, despite high 
sequence homology, AAV1 and 6 may not necessarily perform 
similarly in the heart. In addition, the nonhuman primates were 
injected within 1 hour of birth, and because protein expression 
profiles change throughout development, the receptors for differ-
ent AAV serotypes may be differentially expressed in the neonate 
compared to the adult. A comprehensive comparison of AAV 
serotypes in adult nonhuman primate hearts, which would be the 
large animal model phylogenetically closest to humans, may be 
necessary to identify the ideal vector for human clinical trials.
This novel protocol has great therapeutic potential because 
it can be safely used to transfer a vector capable of rapid onset, 
efficient, long-term expression to the heart via a simple, relatively 
noninvasive procedure. Its potential applications are numerous, 
and include most forms of acquired and genetic cardiomyopa-
thy in both the veterinary and human setting. Limitations of our 
study include a short follow-up period after procedure and lack 
of experience with specific therapeutic transgenes. This period 
was necessitated by the reporter transgene used in our study. GFP 
expression was analyzed 7–10 days after injection so that we could 
appreciate true transfer efficiency before a T-cell response against 
the cells expressing the foreign reporter protein was mounted.21 
However, injection of empty capsid (AAV6) in three dogs did not 
result in any clinical or myocardial change for 6 months after pro-
cedure, and no T cells reactive to AAV6 capsid were detected by 
enzyme-linked immunosorbent spot (Supplementary Figure S4 
and Supplementary Materials and Methods). This suggests that 
AAV6 has potential as a long-term expression vector in the heart, 
which is important in light of a recent report which described 
a cellular immune response against the capsids of AAV2 and 6 
 following direct injection into canine skeletal muscle.47 In this 
model, immunosuppression was necessary for long-term expres-
sion.48 It may be noted that the immune response to AAV varies 
from tissue to tissue, and long-term expression in the heart may be 
possible without immune modulation. It is also possible that dif-
ferences in vector preparation could alter the immune response. 
Further studies with nonimmunogenic transgenes are necessary 
in our model to confirm this hypothesis.
Our protocol could be optimized in several ways to meet spe-
cific clinical needs. The DNA packaging capacity of scAAV is lim-
ited to half that of the traditional ssAAV vectors due to the fact that 
a dimeric repeat is encapsidated.15 If lower expression levels and/
or delayed expression could be tolerated, ssAAV6 could be used to 
deliver a much larger therapeutic gene at the cost of less efficient 
and/or delayed expression. For safety, in order to restrict expression 
outside of the heart, transcriptional and/or transductional target-
ing could be used.49 In patients with heart disease, considering the 
frequency of ventricular ectopy in our healthy dogs, a lidocaine-
constant rate infusion should probably be initiated at the time of 
anesthetic induction. Finally, increased expression efficiency may 
be achieved by increasing the number and/or volume of injections, 
and delivery could easily be directed to the right ventricle following 
a femoral or jugular vein catheterization. Investigation is underway 
to evaluate the feasibility of these approaches.
MAterIAls And Methods
Vector design and production. Each vector was designed to express the 
EGFP reporter gene under control of the constitutive chicken β-actin 
promoter with cytomegalovirus enhancer (CB promoter). Vectors were 
produced according to the previously described pseudotyping protocol by 
the Vector Core of the University of Pennsylvania.11 Briefly, recombinant 
AAV genomes containing AAV2 inverted terminal repeats were packaged 
by triple transfection of 293 cells with a cis-plasmid containing the EGFP 
transgene, an adenovirus helper plasmid, and a chimeric trans-plasmid 
containing the AAV2 rep gene fused to the capsid gene of the AAV sero-
type of interest. Self-complementary vectors contained a mutation in the 
termination sequence of the 5′-inverted terminal repeat to allow synthesis 
and encapsidation of a dimeric inverted repeat of the transgene cassette.15
Animal use and vector delivery protocol. All animals were handled in com-
pliance with National Institutes of Health and institutional guidelines that 
were approved by the Institutional Animal Care and Use Committee of the 
University of Pennsylvania. Twenty mongrel dogs (5–10 kg, 3–6 months 
old) were used in this study. Sixteen mongrel dogs were randomized to 
receive one of the four vectors: ssAAV9, scAAV9, scAAV8, or scAAV6 (n = 
4 per group). An additional dog received saline-only injection to serve as 
a negative control for GFP fluorescence and biodistribution studies, and 
three dogs were treated with AAV6 empty capsid for long-term (6 months) 
1958 www.moleculartherapy.org  vol. 16 no. 12 dec. 2008 
© The American Society of Gene Therapy
Global Gene Transfer to Canine Heart via scAAV6
safety evaluation. Pre-existing, neutralizing antibody titer for AAV9, 8, and 
6 was determined in a subset of canines (n = 8) from the colony, all of which 
were vaccinated against parvovirus. Titer was determined by incubating 
Huh7 cells with serial dilutions of canine serum and AAV-CMV-EGFP of 
the serotype in question and observing the dilution at which the number of 
GFP-positive cells was reduced by 50% compared to control wells.
Procedures were performed under general anesthesia, and dogs 
were placed in left lateral recumbency. Heart rate, respiratory rate, 
systolic blood pressure, electrocardiogram, and oxygen saturation were 
monitored throughout the anesthetic period. In a subset of dogs (n = 6), 
transesophageal echocardiography was also performed throughout the 
procedure to monitor patency of the aortic valve.
A right carotid arterotomy was performed, and a 7-French introducer 
was placed in the vessel, followed by insertion of the injection catheter. 
This catheter was a steerable injection catheter with an adjustable length 
core needle (MyoCath; Bioheart, Sunrise, FL),42 which has previously 
been used to deliver skeletal myoblasts to large animals and humans.40–43 
The catheter was flushed with heparinized blood before vector infusion 
to prevent inactivation of the virus.50 Next, under fluoroscopic guidance, 
the catheter was advanced into the left ventricular cavity, and by steering 
the needle-tip and adjusting the needle length, ~40 transendocardial 
injections of 250 μl each were performed to target the LVFW and IVS 
from base to apex and from endocardium to epicardium with AAV vector. 
Contrast media was added to the vector solution so that injection sites 
could be visualized. This allowed us to differentiate between injected 
and uninjected regions of the heart and helped to ensure that the vector 
solution was distributed globally throughout the myocardium. Still 
fluoroscopy images recorded during the procedure demonstrate how 
the catheter tip can be deformed to target a specific region of the heart 
(Supplementary Figure S3a) and how contrast media was used to track 
single (Supplementary Figure S3a) and multiple (Supplementary 
Figure S3b) injections during the same procedure.
A dose of 2 × 1013  gc/kg was used for ssAAV9; however, a lower dose 
(5 × 1011 gc/kg) was used for the self-complementary vector injections. 
For each procedure, vector was mixed with 2 cc of sterile contrast solution 
(Omnipaque) and diluted with sterile saline to produce 10 cc for injection. 
Lidocaine (2 mg/kg as a bolus followed by a constant rate infusion at 
50 μg/kg/min) was initiated if ventricular tachycardia developed during 
the procedure (14 of 16 dogs). After recovery, dogs were treated with 
carprofen for 2 days and amoxicillin–clavulanic acid for 5 days.
Histological analysis of transgene expression and pathology. Dogs were 
killed 7–10 days following treatment and tissues were harvested for deter-
mination of reporter transgene expression and vector biodistribution. For 
analysis of GFP fluorescence, the heart was divided into four sections along 
the short axis from the apex to base and fixed in 4% paraformaldehyde 
overnight at 4 °C. The tissue was then washed 3 × 10 minutes in phosphate-
buffered saline and dehydrated in 20% sucrose overnight at 4 °C. Next, each 
section was frozen in optimal cutting temperature embedding compound 
(Tissue-Tek; Sakura Finetek, Torrance, CA), and 10-μm cryosections 
were prepared. Slides were mounted with Vectashield 4′-6-diamidino-2-
phenylindole media (Vector Laboratories, Burlingame, CA) and examined 
for GFP fluorescence using a Leitz DMRBE fluorescent microscope (Leica, 
Bannockburn, IL) equipped with a Micro MAX digital camera (Princeton 
Instruments, Trenton, NJ) interfaced with Image Pro Plus software (Media 
Cybernetics, Bethesda, MD). For each animal, four representative photo-
graphs were recorded under constant exposure conditions using the ×10 
objective from the IVS and LVFW from the endocardium to the epicar-
dium in each of the four heart sections, and the area positive for GFP fluo-
rescence was quantified using Open Lab software (Improvision, Waltham, 
MA). The threshold for detection was set above background levels mea-
sured in the negative control, saline-treated dog. Immunofluorescent 
staining for cardiac troponin T (1:50; Santa Cruz Biotechnology, Santa 
Cruz, CA) was also performed, and the GFP-positive area was normalized 
to the troponin-positive area to report the percent cardiomyocyte area pos-
itive for GFP. A sample of liver from each animal was also fixed, sectioned, 
and analyzed as described above to quantify GFP-positive hepatocytes. For 
pathological analysis, slides were stained independently with hematoxylin 
and eosin and trichrome (Sigma, St. Louis, MO) to identify mononuclear 
infiltrate and fibrosis, respectively.
Biodistribution analysis. For biodistribution analysis, samples were snap-
frozen in liquid nitrogen. Following DNA extraction, genome copy titers 
were quantified by TaqMan PCR (Applied Biosystems, Foster City, CA) 
using primers and probes designed against the EGFP transgene. One 
microgram of template DNA was used for each reaction, and several con-
trols were performed to confirm the specificity and accuracy of the PCR. 
A spike control was performed in which the test sample was spiked with 
exogenous test assay target to rule out PCR inhibition. The assay was also 
performed on samples from the negative control, saline-injected animal to 
determine background signal of the assay, which was negligible (<1 gc per 
5,000 cells, or >1 log lower than the minimum gc detected in experimental 
samples). Finally, a control endogenous gene (glyceraldehyde 3-phosphate 
dehydrogenase) was run as a loading control and displayed minimal sam-
ple to sample variation (<0.25 cycles) with 1-μg template DNA.
Statistical analysis. Mean values from each experimental group were 
compared using the two-tailed Student’s t-test or one-way ANOVA with 
Student–Newman–Keuls post hoc analysis.
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Figure S1. Representative cardiac sections from each vector and sa-
line control demonstrating GFP fluorescence with DAPI counterstain.
Figure S2. Representative cardiac sections from an AAV-injected ca-
nine and uninjected control stained with H&E and trichrome.
Figure S3. Delivery of AAV via deformable injection catheter under 
fluoroscopic guidance.
Figure S4. Representative ELISpot data from a canine treated with 
AAV6 empty capsid.
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